原发性肝癌患者血清补体C3水平的临床检测意义  

作　　者：张金彦[1] 张帆[1] 黄涛[2] 徐军明[1] 彭志海[1] 

机构地区：[1]上海交通大学附属第一人民医院普外科,200080 [2]上海交通大学附属第一人民医院宝山分院检验科,200940

出　　处：《浙江临床医学》2015年第6期861-862,共2页Zhejiang Clinical Medical Journal

基　　金：国家自然科学基金（81200328）;上海市自然科学基金（12ZR1424100）;上海市第一人民医院优青计划基金（061251）

摘　　要：目的：探讨原发性肝癌患者血清补体水平检测的临床意义。方法收集分析167例肝脏疾病患者的性别、年龄、病理等信息与血清补体水平相关性。结果血清C3水平原发性肝癌组显著高于乙肝后肝硬化组（P〈0.05）；巨大肝癌组的血清C3水平显著高于大肝癌组与小肝癌组（P〈0.05）；高分化组的血清C3水平明显高于中分化组与低分化组（P〈0.05）。结论血清补体C3水平与肝癌大小、病理分型等相关，对评估病情进展有一定价值。Objective To assess the effect of serum complement levels of patients on the primary hepatic carcinoma. Method 167 patients with liver diseases were observed,including 125 cases with hepatocellular carcinoma and 42 cases with cirrhosis following hepatitis B. The patients＇ general information,serum complement levels,and pathology reports were collected and analyzed. Result The difference of the complement levels between different liver disease,or different pathological types and different size of primary hepatic carcinoma were significant （P〈0.05）. Conclusion Detection of serum complement levels is benefit for evaluation the disease process of the patients with hepatocellular carcinoma.

关 键 词：C3 补体 肝癌 肝硬化 

分 类 号：R512.62[医药卫生—内科学]